At MannKind, we’re developing new ways to help people take control of their health and get the most out of life. Our ultra rapid-acting, inhalable insulin, Afrezza®, offers glucose management in the moment for people living with diabetes, and our novel inhalation-based technologies have the potential to lead to freer, healthier, and happier lives.
By working with other organizations, our breakthroughs can help more people live life more humann. From formulation and reformulation ideas to global licensing opportunities for Afrezza®, we have the capabilities to create partnerships that can create a world without limit for all.partner with us explore our pipeline
For too long, many fast-acting medications have required injections—and all the pain and inconvenience that comes with them. MannKind’s Technosphere® Technology is an innovative, dry-powder formulation technology that allows medication to be delivered through the lungs instead.
Technosphere® Technology can be applied to a number of important therapeutic areas, including metabolic diseases like diabetes, respiratory diseases, and other conditions requiring acute drug delivery, such as pain management.
Most importantly, inhaled medicine offers an alternative to injections, helping people get the therapies they need and get back to being humann. MannKind has partnered with several organizations to leverage Technosphere® Technology to help change more lives for the better.
Diabetes has shaped the lives of people around the world. In 2019, 463 million adults were living with diabetes, and about 700 million will be by 2045.1
To provide more carefree, worry-free moments to this growing group of people, MannKind has developed Afrezza®. An ultra rapid-acting, inhaled insulin, Afrezza® offers glucose management in the moment for adults living with type 1 or type 2 diabetes. Now, we’re working to offer Afrezza® to more people globally. We currently have partnerships in Brazil and India; for commercial opportunities in other regions, contact firstname.lastname@example.org.
1. International Diabetes Federation, “Diabetes facts & figures.” https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Accessed March 2020.
BluHale® helps make our simple inhaler even easier to use. The novel device is mounted on the inhaler and senses the change in pressure when a user inhales through the mouthpiece. This information is relayed via a Bluetooth connection to a smartphone app, helping the user learn more effective inhalation techniques.
Our BluHale® Pro edition is coming soon for healthcare providers to use during in-office training, and we are working on a BluHale® consumer edition that will include additional sensors to detect device orientation and dosage strength. While BluHale® is not used to diagnose or manage health, we envision BluHale® as part of a connected care ecosystem that will be used to help people more easily manage their conditions and more fully live their lives.
Together, we can bring life more humann to more people across the country.
MannKind has built a sales force of more than 80 dedicated pharmaceutical professionals who call on prescribers nationwide, supported by field-based managers and managed care executives. Our corporate headquarters is home to our Customer Experience Center, which helps prescribers and everyone who uses our therapies with reimbursement, product training, and other questions.
We believe our team can be leveraged to support additional products associated with diabetes or orphan lung diseases. Contact us for more information.partner with us